Cargando…
Genetically increased circulating FUT3 level leads to reduced risk of idiopathic pulmonary fibrosis: a Mendelian randomisation study
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal fibrotic interstitial lung disease. Few circulating biomarkers have been identified to have causal effects on IPF. METHODS: To identify candidate IPF-influencing circulating proteins, we undertook an efficient screen of circulat...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828995/ https://www.ncbi.nlm.nih.gov/pubmed/34172473 http://dx.doi.org/10.1183/13993003.03979-2020 |
_version_ | 1784647968252493824 |
---|---|
author | Nakanishi, Tomoko Cerani, Agustin Forgetta, Vincenzo Zhou, Sirui Allen, Richard J. Leavy, Olivia C. Koido, Masaru Assayag, Deborah Jenkins, R. Gisli Wain, Louise V. Yang, Ivana V. Lathrop, G. Mark Wolters, Paul J. Schwartz, David A. Richards, J. Brent |
author_facet | Nakanishi, Tomoko Cerani, Agustin Forgetta, Vincenzo Zhou, Sirui Allen, Richard J. Leavy, Olivia C. Koido, Masaru Assayag, Deborah Jenkins, R. Gisli Wain, Louise V. Yang, Ivana V. Lathrop, G. Mark Wolters, Paul J. Schwartz, David A. Richards, J. Brent |
author_sort | Nakanishi, Tomoko |
collection | PubMed |
description | BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal fibrotic interstitial lung disease. Few circulating biomarkers have been identified to have causal effects on IPF. METHODS: To identify candidate IPF-influencing circulating proteins, we undertook an efficient screen of circulating proteins by applying a two-sample Mendelian randomisation (MR) approach with existing publicly available data. For instruments, we used genetic determinants of circulating proteins which reside cis to the encoded gene (cis-single nucleotide polymorphisms (SNPs)), identified by two genome-wide association studies (GWASs) in European individuals (3301 and 3200 subjects). We then applied MR methods to test if the levels of these circulating proteins influenced IPF susceptibility in the largest IPF GWAS (2668 cases and 8591 controls). We validated the MR results using colocalisation analyses to ensure that both the circulating proteins and IPF shared a common genetic signal. RESULTS: MR analyses of 834 proteins found that a 1 sd increase in circulating galactoside 3(4)-l-fucosyltransferase (FUT3) and α-(1,3)-fucosyltransferase 5 (FUT5) was associated with a reduced risk of IPF (OR 0.81, 95% CI 0.74–0.88; p=6.3×10(−7) and OR 0.76, 95% CI 0.68–0.86; p=1.1×10(−5), respectively). Sensitivity analyses including multiple cis-SNPs provided similar estimates both for FUT3 (inverse variance weighted (IVW) OR 0.84, 95% CI 0.78–0.91; p=9.8×10(−6) and MR-Egger OR 0.69, 95% CI 0.50–0.97; p=0.03) and FUT5 (IVW OR 0.84, 95% CI 0.77–0.92; p=1.4×10(−4) and MR-Egger OR 0.59, 95% CI 0.38–0.90; p=0.01). FUT3 and FUT5 signals colocalised with IPF signals, with posterior probabilities of a shared genetic signal of 99.9% and 97.7%, respectively. Further transcriptomic investigations supported the protective effects of FUT3 for IPF. CONCLUSIONS: An efficient MR scan of 834 circulating proteins provided evidence that genetically increased circulating FUT3 level is associated with reduced risk of IPF. |
format | Online Article Text |
id | pubmed-8828995 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-88289952022-02-11 Genetically increased circulating FUT3 level leads to reduced risk of idiopathic pulmonary fibrosis: a Mendelian randomisation study Nakanishi, Tomoko Cerani, Agustin Forgetta, Vincenzo Zhou, Sirui Allen, Richard J. Leavy, Olivia C. Koido, Masaru Assayag, Deborah Jenkins, R. Gisli Wain, Louise V. Yang, Ivana V. Lathrop, G. Mark Wolters, Paul J. Schwartz, David A. Richards, J. Brent Eur Respir J Original Research Articles BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal fibrotic interstitial lung disease. Few circulating biomarkers have been identified to have causal effects on IPF. METHODS: To identify candidate IPF-influencing circulating proteins, we undertook an efficient screen of circulating proteins by applying a two-sample Mendelian randomisation (MR) approach with existing publicly available data. For instruments, we used genetic determinants of circulating proteins which reside cis to the encoded gene (cis-single nucleotide polymorphisms (SNPs)), identified by two genome-wide association studies (GWASs) in European individuals (3301 and 3200 subjects). We then applied MR methods to test if the levels of these circulating proteins influenced IPF susceptibility in the largest IPF GWAS (2668 cases and 8591 controls). We validated the MR results using colocalisation analyses to ensure that both the circulating proteins and IPF shared a common genetic signal. RESULTS: MR analyses of 834 proteins found that a 1 sd increase in circulating galactoside 3(4)-l-fucosyltransferase (FUT3) and α-(1,3)-fucosyltransferase 5 (FUT5) was associated with a reduced risk of IPF (OR 0.81, 95% CI 0.74–0.88; p=6.3×10(−7) and OR 0.76, 95% CI 0.68–0.86; p=1.1×10(−5), respectively). Sensitivity analyses including multiple cis-SNPs provided similar estimates both for FUT3 (inverse variance weighted (IVW) OR 0.84, 95% CI 0.78–0.91; p=9.8×10(−6) and MR-Egger OR 0.69, 95% CI 0.50–0.97; p=0.03) and FUT5 (IVW OR 0.84, 95% CI 0.77–0.92; p=1.4×10(−4) and MR-Egger OR 0.59, 95% CI 0.38–0.90; p=0.01). FUT3 and FUT5 signals colocalised with IPF signals, with posterior probabilities of a shared genetic signal of 99.9% and 97.7%, respectively. Further transcriptomic investigations supported the protective effects of FUT3 for IPF. CONCLUSIONS: An efficient MR scan of 834 circulating proteins provided evidence that genetically increased circulating FUT3 level is associated with reduced risk of IPF. European Respiratory Society 2022-02-10 /pmc/articles/PMC8828995/ /pubmed/34172473 http://dx.doi.org/10.1183/13993003.03979-2020 Text en Copyright ©The authors 2022. https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org) |
spellingShingle | Original Research Articles Nakanishi, Tomoko Cerani, Agustin Forgetta, Vincenzo Zhou, Sirui Allen, Richard J. Leavy, Olivia C. Koido, Masaru Assayag, Deborah Jenkins, R. Gisli Wain, Louise V. Yang, Ivana V. Lathrop, G. Mark Wolters, Paul J. Schwartz, David A. Richards, J. Brent Genetically increased circulating FUT3 level leads to reduced risk of idiopathic pulmonary fibrosis: a Mendelian randomisation study |
title | Genetically increased circulating FUT3 level leads to reduced risk of idiopathic pulmonary fibrosis: a Mendelian randomisation study |
title_full | Genetically increased circulating FUT3 level leads to reduced risk of idiopathic pulmonary fibrosis: a Mendelian randomisation study |
title_fullStr | Genetically increased circulating FUT3 level leads to reduced risk of idiopathic pulmonary fibrosis: a Mendelian randomisation study |
title_full_unstemmed | Genetically increased circulating FUT3 level leads to reduced risk of idiopathic pulmonary fibrosis: a Mendelian randomisation study |
title_short | Genetically increased circulating FUT3 level leads to reduced risk of idiopathic pulmonary fibrosis: a Mendelian randomisation study |
title_sort | genetically increased circulating fut3 level leads to reduced risk of idiopathic pulmonary fibrosis: a mendelian randomisation study |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828995/ https://www.ncbi.nlm.nih.gov/pubmed/34172473 http://dx.doi.org/10.1183/13993003.03979-2020 |
work_keys_str_mv | AT nakanishitomoko geneticallyincreasedcirculatingfut3levelleadstoreducedriskofidiopathicpulmonaryfibrosisamendelianrandomisationstudy AT ceraniagustin geneticallyincreasedcirculatingfut3levelleadstoreducedriskofidiopathicpulmonaryfibrosisamendelianrandomisationstudy AT forgettavincenzo geneticallyincreasedcirculatingfut3levelleadstoreducedriskofidiopathicpulmonaryfibrosisamendelianrandomisationstudy AT zhousirui geneticallyincreasedcirculatingfut3levelleadstoreducedriskofidiopathicpulmonaryfibrosisamendelianrandomisationstudy AT allenrichardj geneticallyincreasedcirculatingfut3levelleadstoreducedriskofidiopathicpulmonaryfibrosisamendelianrandomisationstudy AT leavyoliviac geneticallyincreasedcirculatingfut3levelleadstoreducedriskofidiopathicpulmonaryfibrosisamendelianrandomisationstudy AT koidomasaru geneticallyincreasedcirculatingfut3levelleadstoreducedriskofidiopathicpulmonaryfibrosisamendelianrandomisationstudy AT assayagdeborah geneticallyincreasedcirculatingfut3levelleadstoreducedriskofidiopathicpulmonaryfibrosisamendelianrandomisationstudy AT jenkinsrgisli geneticallyincreasedcirculatingfut3levelleadstoreducedriskofidiopathicpulmonaryfibrosisamendelianrandomisationstudy AT wainlouisev geneticallyincreasedcirculatingfut3levelleadstoreducedriskofidiopathicpulmonaryfibrosisamendelianrandomisationstudy AT yangivanav geneticallyincreasedcirculatingfut3levelleadstoreducedriskofidiopathicpulmonaryfibrosisamendelianrandomisationstudy AT lathropgmark geneticallyincreasedcirculatingfut3levelleadstoreducedriskofidiopathicpulmonaryfibrosisamendelianrandomisationstudy AT wolterspaulj geneticallyincreasedcirculatingfut3levelleadstoreducedriskofidiopathicpulmonaryfibrosisamendelianrandomisationstudy AT schwartzdavida geneticallyincreasedcirculatingfut3levelleadstoreducedriskofidiopathicpulmonaryfibrosisamendelianrandomisationstudy AT richardsjbrent geneticallyincreasedcirculatingfut3levelleadstoreducedriskofidiopathicpulmonaryfibrosisamendelianrandomisationstudy |